Glycated Albumin Assay Market by Product, Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User

Description

List of Tables

[197 Pages Report] The Glycated Albumin Assay Market size was estimated at USD 217.29 million in 2023 and expected to reach USD 232.69 million in 2024, at a CAGR 7.51% to reach USD 360.92 million by 2030.

The glycated albumin assay is a diagnostic test used to measure the amount of glycated albumin in the blood. Glycated albumin is a form of albumin, which is an abundant protein in human blood plasma and has bonded with glucose. It facilitates rapid adjustments in diabetes management strategies, potentially leading to better short-term control of blood glucose levels. It offers an alternative for people for whom HbA1c tests might not be accurate, such as those with hemoglobinopathies, recent blood transfusion recipients, or individuals with chronic kidney or liver diseases. The prevalence of diabetes and rising public awareness about monitoring and controlling blood glucose necessitates accurate and reliable testing methods. However, various countries' reimbursement policies and regulatory frameworks may hinder the widespread use of glycated albumin assays. Expanding healthcare infrastructure in emerging economies provides more significant access to advanced diagnostics tools such as glycated albumin assays, and research into novel biomarkers for glucose regulation is expected to create opportunities for growth of the glycated albumin assay market.

KEY MARKET STATISTICS
Base Year [2023]	USD 217.29 million
Estimated Year [2024]	USD 232.69 million
Forecast Year [2030]	USD 360.92 million
CAGR (%)	7.51%

Regional Insights

The Americas represents a significant landscape in the glycated albumin assay market owing to a substantial need for glycated albumin assay due to the high prevalence of diabetes in these countries. Additionally, countries have advanced healthcare systems that can support the adoption of innovative diagnostic tools such as glycated albumin assays. The growing aging population in Europe contributes significantly to the increasing need for advanced diagnostics such as glycated albumin assays. EU countries have comprehensive healthcare systems that prioritize early detection of diseases such as diabetes, increasing the glycated albumin assay need in the region. In the Middle East and Africa region, there has been a steady rise in lifestyle-related diseases, including diabetes, due to changing demographics and urbanization. Various programs, initiatives, and investments by legal authorities promoted the adoption of innovative diagnostic techniques in the region. The Asia-Pacific market for glycated albumin assay is expanding rapidly due to the growing prevalence of diabetes, increasing research and development activities, and significant advancements in developing novel techniques for glycated albumin detection.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Glycated Albumin Assay Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of diabetes worldwide
- Government initiatives for early diabetes screening programs

Market Restraints
- Technical limitations of glycated albumin testing

Market Opportunities
- Advancements in technology for improved assay methodologies with enhanced accuracy and sensitivity
- Growing development and use of point-of-care testing (POCT) of GA

Market Challenges
- Limited awareness and presence of alternative techniques

Market Segmentation Analysis
- Product: Increasing use of animal glycated albumin assay to understand disease mechanisms
- Application: Significant adoption of glycated albumin assay for detection of type 1 diabetes owing to prevent health complications
- End User: High usage of glycated albumin assay in diagnostic laboratories

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Glycated Albumin Assay Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Glycated Albumin Assay Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Pioneering Partnership Between John Lewis and Randox Unveils In-Store Blood Testing to Enhance Health Diagnostics

John Lewis joined forces with the diagnostic innovator Randox to introduce in-store blood testing services, marking a significant leap towards convenience in health and wellness. This collaboration, the first in department stores, aims to diminish NHS waiting lists by offering comprehensive health checks for various cancers, diabetes, and heart disease. Leveraging Randox's cutting-edge lab-on-a-chip technology, the partnership seeks to revolutionize cancer diagnostics, potentially reducing invasive procedures and alleviating NHS burdens with savings projected to be around GBP 3 billion annually. This service expansion into genetic testing and checks for vitamin deficiencies underlines a move toward personalized, preventative care. [Published On: 2024-02-26]

Strategic Initiatives to Combat Diabetes and Hypertension in India

The West Bengal State Health Department announced efforts to manage diabetes and hypertension. To incorporate 7.5 million adults into standardized medical care by 2025, the initiative aims to reverse the oversight of these conditions during the COVID-19 pandemic. Specifically, Kolkata seeks to extend care to over 400,000 patients by December 2025. This nationwide campaign involves comprehensive screening efforts, early diagnosis, and timely intervention strategies, particularly targeting adults above 30 through free blood pressure and glucose screenings. These screenings are available at hospitals and community camps, with display signs at critical hospital locations such as OPD ticket counters, encouraging participation. [Published On: 2024-02-24]

Advancing Type 1 Diabetes Care: Enable Biosciences Launches Innovative 'Kit to Clinics' Program Featuring ADAP Technology

Enable Biosciences Inc. rolled out its Kit to Clinics program tailored for type 1 diabetes care, harnessing cutting-edge Antibody Detection by Agglutination-PCR (ADAP) technology. This initiative aimed to transform early diabetes detection and management by providing clinics with a highly reliable testing tool, proven through rigorous, peer-reviewed studies, including impressive outcomes in the Islet Autoantibody Standardization Program evaluations. Endorsed by JDRF, the global player in type 1 diabetes research funding, this program underlines the significance of early diagnosis in leveraging new treatment advancements that can delay diabetes onset. [Published On: 2024-01-23]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Glycated Albumin Assay Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Glycated Albumin Assay Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abcam PLC, Abnova Corporation, AFG Bioscience LLC, Asahi Kasei Corporation, Beijing Jiuqiang Biotechnology Co., Ltd., Biomatik Corporation, Cardinal Health, Inc., Crystal Chem Inc., Cusabio Technology LLC, Diazyme Laboratories, Inc., DxGen Corp., EKF Diagnostics Holdings, Epinex Diagnostics Inc., Hzymes Biotech, Laboratory Corporation of America Holdings, LifeSpan BioSciences, Inc., Merck KGaA, Novatein Biosciences Inc., Sekisui Chemical Co., Ltd., Thermo Fisher Scientific Inc., Thomas Scientific LLC, Weldon Biotech, Inc., and Wuhan Fine Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Glycated Albumin Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Animal Glycated Albumin Assay
- Human Glycated Albumin Assay

Application
- Prediabetes
- Type 1 Diabetes
- Type 2 Diabetes

End User
- Diabetic Care Centres
- Diagnostic Laboratories
- Hospitals & Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-A579C431592C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of diabetes worldwide
  - 5.1.1.2. Government initiatives for early diabetes screening programs
- 5.1.2. Restraints
  - 5.1.2.1. Technical limitations of glycated albumin testing
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in technology for improved assay methodologies with enhanced accuracy and sensitivity
  - 5.1.3.2. Growing development and use of point-of-care testing (POCT) of GA
- 5.1.4. Challenges
  - 5.1.4.1. Limited awareness and presence of alternative techniques
5.2. Market Segmentation Analysis
- 5.2.1. Product: Increasing use of animal glycated albumin assay to understand disease mechanisms
- 5.2.2. Application: Significant adoption of glycated albumin assay for detection of type 1 diabetes owing to prevent health complications
- 5.2.3. End User: High usage of glycated albumin assay in diagnostic laboratories
5.3. Market Trend Analysis
- 5.3.1. Rising incidences of diabetes, and robust healthcare sector in the Americas region
- 5.3.2. Exponential diabetes awareness programs improving the availability and preference for glycated albumin assay kits across the Asia-Pacific
- 5.3.3. Expanding availability of patents for glycated albumin assays with increasing healthcare expenditure in EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Glycated Albumin Assay Market, by Product

6.1. Introduction
6.2. Animal Glycated Albumin Assay
6.3. Human Glycated Albumin Assay

7. Glycated Albumin Assay Market, by Application

7.1. Introduction
7.2. Prediabetes
7.3. Type 1 Diabetes
7.4. Type 2 Diabetes

8. Glycated Albumin Assay Market, by End User

8.1. Introduction
8.2. Diabetic Care Centres
8.3. Diagnostic Laboratories
8.4. Hospitals & Clinics

9. Americas Glycated Albumin Assay Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Glycated Albumin Assay Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Glycated Albumin Assay Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Pioneering Partnership Between John Lewis and Randox Unveils In-Store Blood Testing to Enhance Health Diagnostics
- 12.3.2. Strategic Initiatives to Combat Diabetes and Hypertension in India
- 12.3.3. Advancing Type 1 Diabetes Care: Enable Biosciences Launches Innovative 'Kit to Clinics' Program Featuring ADAP Technology
- 12.3.4. Pioneering Innovations in Biotechnology: Recognizing the Achievements of WRCP IIT Faculty in Securing Biotechnology Ignition Grants
- 12.3.5. ELSA Study: Pioneering Early Detection and Management of Type 1 Diabetes in UK Children
- 12.3.6. Precision Diabetes, Inc. Partners with DxGen Corp. to Revolutionize Point-of-Care Diabetes Testing with the Launch of Epithod AutoDx
- 12.3.7. Introduction of the FDA-Cleared Lucica Glycated Albumin-L Test Kit by EKF Diagnostics
12.4. Strategy Analysis & Recommendation
- 12.4.1. Abcam PLC
- 12.4.2. Asahi Kasei Corporation
- 12.4.3. Cardinal Health, Inc.
- 12.4.4. Diazyme Laboratories, Inc.
- 12.4.5. EKF Diagnostics Holdings PLC
- 12.4.6. Epinex Diagnostics Inc.
- 12.4.7. Laboratory Corporation of America Holdings
- 12.4.8. Sekisui Chemical Co., Ltd.
- 12.4.9. Cusabio Technology LLC
- 12.4.10. Thermo Fisher Scientific Inc.

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio